[Rhabdomyolysis associated with long-term treatment of esomeprazole]

Nihon Shokakibyo Gakkai Zasshi. 2018;115(3):299-304. doi: 10.11405/nisshoshi.115.299.
[Article in Japanese]

Abstract

Proton pump inhibitors (PPIs) have been widely used in the treatment of gastroesophageal reflux disease and peptic ulcer disease. Although they have a potent acid suppressive effect and excellent efficacy in acid-related diseases, PPI-induced rhabdomyolysis has been reported. Here, we report the case of a patient with reflux esophagitis who developed rhabdomyolysis after esomeprazole treatment. A 67-year-old man with reflux esophagitis who had started esomeprazole treatment for the preceding 10 months complained of back and limb fatigue and myalgia. His serum creatinine kinase (CK) level was markedly elevated, and CK isozyme exhibited an MM pattern. He was diagnosed with rhabdomyolysis induced by esomeprazole. The cessation of esomeprazole rapidly improved his symptoms, and the serum CK level was normalized within 16 days. PPI-induced rhabdomyolysis is a rare complication. In most cases, PPI-induced rhabdomyolysis occurs within 3 months after starting PPIs. However, rhabdomyolysis occurred at 10 months after starting esomeprazole treatment in our patient. Early diagnosis of PPI-induced rhabdomyolysis is required even in long-term PPI users.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Esomeprazole / adverse effects*
  • Esomeprazole / therapeutic use
  • Esophagitis, Peptic
  • Gastroesophageal Reflux
  • Humans
  • Male
  • Proton Pump Inhibitors / adverse effects*
  • Proton Pump Inhibitors / therapeutic use
  • Rhabdomyolysis / chemically induced
  • Rhabdomyolysis / diagnosis*
  • Rhabdomyolysis / therapy
  • Treatment Outcome

Substances

  • Proton Pump Inhibitors
  • Esomeprazole